Literature DB >> 34099894

Schwann cell gene therapies in sight.

Stephan Züchner1.   

Abstract

Entities:  

Mesh：

Year:  2021        PMID： 34099894      PMCID： PMC8602750          DOI： 10.1038/s41434-021-00264-8

Source DB:  PubMed          Journal:  Gene Ther        ISSN： 0969-7128            Impact factor:   5.250


× No keyword cloud information.
  10 in total

1.  The effects of a dominant connexin32 mutant in myelinating Schwann cells.

Authors:  Linda Jo Bone Jeng; Rita J Balice-Gordon; Albee Messing; Kenneth H Fischbeck; Steven S Scherer
Journal:  Mol Cell Neurosci       Date:  2006-06-21       Impact factor: 4.314

2.  Genetic and clinical aspects of Charcot-Marie-Tooth's disease.

Authors:  H Skre
Journal:  Clin Genet       Date:  1974       Impact factor: 4.438

3.  Studies in transgenic mice indicate a loss of connexin32 function in X-linked Charcot-Marie-Tooth disease.

Authors:  A Abel; L J Bone; A Messing; S S Scherer; K H Fischbeck
Journal:  J Neuropathol Exp Neurol       Date:  1999-07       Impact factor: 3.685

4.  Transgenic expression of human connexin32 in myelinating Schwann cells prevents demyelination in connexin32-null mice.

Authors:  Steven S Scherer; Yi-Tian Xu; Albee Messing; Klaus Willecke; Kenneth H Fischbeck; Linda Jo Bone Jeng
Journal:  J Neurosci       Date:  2005-02-09       Impact factor: 6.167

Review 5.  Comparison of high-dose intracisterna magna and lumbar puncture intrathecal delivery of AAV9 in mice to treat neuropathies.

Authors:  Rachel M Bailey; Alejandra Rozenberg; Steven J Gray
Journal:  Brain Res       Date:  2020-04-11       Impact factor: 3.252

6.  Connexin32-null mice develop demyelinating peripheral neuropathy.

Authors:  S S Scherer; Y T Xu; E Nelles; K Fischbeck; K Willecke; L J Bone
Journal:  Glia       Date:  1998-09       Impact factor: 7.452

7.  Connexin32 mutations cause loss of function in Schwann cells and oligodendrocytes leading to PNS and CNS myelination defects.

Authors:  Irene Sargiannidou; Natalie Vavlitou; Sophia Aristodemou; Andreas Hadjisavvas; Kyriacos Kyriacou; Steven S Scherer; Kleopas A Kleopa
Journal:  J Neurosci       Date:  2009-04-15       Impact factor: 6.167

8.  CMT subtypes and disease burden in patients enrolled in the Inherited Neuropathies Consortium natural history study: a cross-sectional analysis.

Authors:  V Fridman; B Bundy; M M Reilly; D Pareyson; C Bacon; J Burns; J Day; S Feely; R S Finkel; T Grider; C A Kirk; D N Herrmann; M Laurá; J Li; T Lloyd; C J Sumner; F Muntoni; G Piscosquito; S Ramchandren; R Shy; C E Siskind; S W Yum; I Moroni; E Pagliano; S Zuchner; S S Scherer; M E Shy
Journal:  J Neurol Neurosurg Psychiatry       Date:  2014-11-27       Impact factor: 10.154

9.  Development of Intrathecal AAV9 Gene Therapy for Giant Axonal Neuropathy.

Authors:  Rachel M Bailey; Diane Armao; Sahana Nagabhushan Kalburgi; Steven J Gray
Journal:  Mol Ther Methods Clin Dev       Date:  2018-02-15       Impact factor: 6.698

10.  AAV9-mediated Schwann cell-targeted gene therapy rescues a model of demyelinating neuropathy.

Authors:  Alexia Kagiava; Christos Karaiskos; Jan Richter; Christina Tryfonos; Matthew J Jennings; Amanda J Heslegrave; Irene Sargiannidou; Marina Stavrou; Henrik Zetterberg; Mary M Reilly; Christina Christodoulou; Rita Horvath; Kleopas A Kleopa
Journal:  Gene Ther       Date:  2021-03-10       Impact factor: 5.250
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.